NASDAQ:CBIO Crescent Biopharma (CBIO) Stock Price, News & Analysis $13.69 +0.46 (+3.48%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesOwnershipSEC FilingsSustainabilityTrendsBuy This Stock About Crescent Biopharma Stock (NASDAQ:CBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Crescent Biopharma alerts:Sign Up Key Stats Today's Range$13.01▼$13.8050-Day Range$11.00▼$16.9052-Week Range$10.83▼$63.00Volume64,236 shsAverage Volume46,573 shsMarket Capitalization$267.64 millionP/E RatioN/ADividend YieldN/APrice Target$25.60Consensus RatingBuy Company Overview Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA. Read More Crescent Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreCBIO MarketRank™: Crescent Biopharma scored higher than 75% of companies evaluated by MarketBeat, and ranked 263rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.7 / 5Analyst RatingBuy Consensus RatingCrescent Biopharma has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCrescent Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Crescent Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Crescent Biopharma are expected to grow in the coming year, from ($0.16) to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crescent Biopharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crescent Biopharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrescent Biopharma has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CBIO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCrescent Biopharma does not currently pay a dividend.Dividend GrowthCrescent Biopharma does not have a long track record of dividend growth. Sustainability and ESG3.7 / 5Environmental Score-0.84 Short InterestThere is no current short interest data available for CBIO. News and Social Media2.3 / 5News Sentiment0.10 News SentimentCrescent Biopharma has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Crescent Biopharma this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added Crescent Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Crescent Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Crescent Biopharma is held by insiders.Percentage Held by Institutions75.19% of the stock of Crescent Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Crescent Biopharma's insider trading history. Receive CBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crescent Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CBIO Stock News HeadlinesCrescent Biopharma (NASDAQ:CBIO) Receives Buy Rating from HC WainwrightAugust 29, 2025 | americanbankingnews.comCrescent Biopharma to Present at September Investor ConferencesAugust 28, 2025 | globenewswire.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.September 4 at 2:00 AM | American Alternative (Ad)Jefferies Financial Group Begins Coverage on Crescent Biopharma (NASDAQ:CBIO)August 27, 2025 | americanbankingnews.comJefferies Initiates Coverage of Crescent Biopharma (CBIO) with Buy RecommendationAugust 25, 2025 | msn.comCrescent Biopharma initiated with a Buy at JefferiesAugust 25, 2025 | msn.comCrescent Biopharma: Chasing The Summit HypeAugust 18, 2025 | seekingalpha.comHC Wainwright & Co. Initiates Coverage of Crescent Biopharma (CBIO) with Buy RecommendationAugust 12, 2025 | msn.comSee More Headlines CBIO Stock Analysis - Frequently Asked Questions How have CBIO shares performed this year? Crescent Biopharma's stock was trading at $15.7950 on January 1st, 2025. Since then, CBIO stock has decreased by 13.3% and is now trading at $13.69. How were Crescent Biopharma's earnings last quarter? Crescent Biopharma, Inc. (NASDAQ:CBIO) issued its quarterly earnings results on Thursday, August, 17th. The biopharmaceutical company reported ($7.00) EPS for the quarter, hitting the consensus estimate of ($7.00). When did Crescent Biopharma's stock split? Crescent Biopharma shares reverse split before market open on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Crescent Biopharma's major shareholders? Top institutional investors of Crescent Biopharma include BVF Inc. IL (7.10%), Commodore Capital LP (2.32%), Perceptive Advisors LLC (2.32%) and Frazier Life Sciences Management L.P. (2.32%). View institutional ownership trends. How do I buy shares of Crescent Biopharma? Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Crescent Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crescent Biopharma investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV). Company Calendar Last Earnings8/17/2023Today9/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBiotechnology Current SymbolNASDAQ:CBIO Previous SymbolNASDAQ:CBIO CIK1253689 Webwww.crescentbiopharma.com Phone617-465-0586Fax336-480-2107Employees50Year Founded2003Price Target and Rating Average Price Target for Crescent Biopharma$25.60 High Price Target$28.00 Low Price Target$22.00 Potential Upside/Downside+92.2%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($34.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$37.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-106.06% Return on Assets-86.60% Debt Debt-to-Equity RatioN/A Current Ratio9.21 Quick Ratio9.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.92 per share Price / Book1.92Miscellaneous Outstanding Shares19,550,000Free Float17,849,000Market Cap$260.41 million OptionableNo Data Beta1.59 Social Links 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:CBIO) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescent Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescent Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.